- Home
- FLYE vs BLRX Comparison
FLYE vs BLRX Comparison
Compare FLYE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- BLRX
- Stock Information
- Founded
- FLYE 2018
- BLRX 2003
- Country
- FLYE United States
- BLRX Israel
- Employees
- FLYE N/A
- BLRX N/A
- Industry
- FLYE Aerospace
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- BLRX Health Care
- Exchange
- FLYE Nasdaq
- BLRX Nasdaq
- Market Cap
- FLYE 10.2M
- BLRX 12.1M
- IPO Year
- FLYE 2024
- BLRX 2011
- Fundamental
- Price
- FLYE $0.61
- BLRX $5.74
- Analyst Decision
- FLYE
- BLRX Strong Buy
- Analyst Count
- FLYE 0
- BLRX 2
- Target Price
- FLYE N/A
- BLRX $19.00
- AVG Volume (30 Days)
- FLYE 220.7K
- BLRX 2.0M
- Earning Date
- FLYE 06-17-2025
- BLRX 05-27-2025
- Dividend Yield
- FLYE N/A
- BLRX N/A
- EPS Growth
- FLYE N/A
- BLRX N/A
- EPS
- FLYE N/A
- BLRX N/A
- Revenue
- FLYE $28,547,111.00
- BLRX $22,340,000.00
- Revenue This Year
- FLYE N/A
- BLRX N/A
- Revenue Next Year
- FLYE N/A
- BLRX N/A
- P/E Ratio
- FLYE N/A
- BLRX N/A
- Revenue Growth
- FLYE N/A
- BLRX 91.68
- 52 Week Low
- FLYE $0.33
- BLRX $2.30
- 52 Week High
- FLYE $7.62
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- BLRX 73.10
- Support Level
- FLYE N/A
- BLRX $3.88
- Resistance Level
- FLYE N/A
- BLRX $7.77
- Average True Range (ATR)
- FLYE 0.00
- BLRX 0.75
- MACD
- FLYE 0.00
- BLRX 0.19
- Stochastic Oscillator
- FLYE 0.00
- BLRX 56.81
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.